Risk factors
Autolus Therapeutics (AUTL) risk factors
Item 1A of every Autolus Therapeutics plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors85 risks10 new6 dropped7 reworded
Financial obligations to Blackstone and BioNTech increase liquidity pressures on Autolus.
Filed Mar 27, 2026 - FY2024 10-K risk factors81 risks
Autolus is an early commercial-stage biopharmaceutical company focused on developing and commercializing engineered T cell therapies like AUCATZYL. The company has incurred significant cumulative losses, including $220.7 million in 2024, and requires substantial additional funding. Operations face heavy regulatory, clinical development, manufacturing, and international risks across the UK, US, and EU.
Filed Mar 20, 2025